Skip to main content

Illinois IGB

Cancer

Erik Nelson - A milestone in my career

February 20, 2023

Several days following the Federal Drug Administration’s approval of a new cancer drug, Erik Nelson (ACPP) was still processing the news.

“It hasn’t sunk in yet that this is actually happening,” he said from his breast cancer research lab in Burrill Hall. “This is why I get up every morning: to hopefully impact a patient's life.”


February 20, 2023


Related Articles

Researchers target prostate cancer with new, rapid biomarker detection method

February 7, 2023

The pivotal role of microRNA in diagnosing and monitoring cancer is well known by today’s researchers. “There have been a lot of studies in recent years linking the presence and concentration of specific microRNA sequences to clinical outcomes for people with advanced prostate cancer,” said Brian Cunningham (CGD leader/MMG), a professor of electrical and computer engineering and a program leader at the Cancer Center at Illinois.


February 7, 2023


Related Articles

First test of anti-cancer agent PAC-1 in human clinical trials shows promise

December 22, 2022

A phase I clinical trial of PAC-1, a drug that spurs programmed cell death in cancer cells, found only minor side effects in patients with end-stage cancers. The drug stalled the growth of tumors in the five people in the trial with neuroendocrine cancers and reduced tumor size in two of those patients. It also showed some therapeutic activity against sarcomas, scientists and clinicians report in the British Journal of Cancer.


December 22, 2022


Related Articles

Researchers receive NCI grant to develop targeted cancer immunotherapies

September 23, 2022

Hua Wang (RBTE), a Materials Science and Engineering assistant professor, was recently awarded a 2.26M Research Project grant from the National Cancer Institute, which will support the development of type 1 conventional dendritic cells (cDC1) targeted cancer vaccines and cytokine therapies through the integration of immune cell homing materials and metabolic glycan labeling.


September 23, 2022


Related Articles

New therapeutic target identified for triple-negative breast cancer

August 26, 2022

Breast cancer is categorized into three major subtypes: hormone receptor-positive, HER2-positive, and triple-negative. Although there are targeted therapeutic approaches for the first two, there are limited options for triple negative-breast cancer patients. In a new study, researchers have discovered that the nuclear receptor TLX can potentially be used for therapeutic intervention.


August 26, 2022


Related Articles

Ultra-sensitive biosensing technique can spot individual molecules that reveal cancer

August 22, 2022

Despite recent years’ dramatic improvements in cancer treatment, cancer remains second only to heart disease as a leading cause of death for Americans. But a new Nature Communications paper has reported exactly the kind of breakthrough that cancer patients yearn for: development of a highly sensitive new method for performing a liquid biopsy that can identify tiny numbers of individual cancer molecules.


August 22, 2022


Related Articles

Immunotherapy Trials Show Promise for Treating Canine Melanoma

August 9, 2022

Dr. Timothy Fan (ACPP), veterinary oncologist and professor at the University of Illinois College of Veterinary Medicine and a Program Leader for the Cancer Center at Illinois, is leading two clinical trials using similar immunotherapies to treat dogs with malignant melanoma. The novel approaches, developed in partnership with cancer researchers based in Boston, have yielded encouraging results in canine patients, and human trials using the same therapeutic platforms are expected to begin in 2023.


August 9, 2022


Related Articles

New engineering approach enhances antibody fragments for cancer therapy

April 21, 2022

Technological advancements over the past few decades have laid the groundwork for the use of microbe-based drugs to treat diseases. Bioengineering professor Shannon Sirk (MME) and her lab are engineering human commensal microbes into living therapeutics, delivering therapeutic proteins directly in the body, to make these drugs more accessible. 


April 21, 2022


Related Articles

Subscribe to Cancer